Namenda (Memantine) | Alzheimer's News Today
WEBNamenda (memantine) is an approved medicine, marketed by Allergan, for the treatment of moderate to severe Alzheimer’s disease (AD). How Namenda works. The brain uses chemical messengers, called neurotransmitters, to pass signals between nerve cells. Different neurotransmitters have different roles; for example, glutamate is involved in learning and memory.
Simufilam (PTI-125) - Alzheimer's News Today
WEBJan 17, 2022 — Simufilam (PTI-125) Last updated Jan. 17, 2022, by Marisa Wexler, MS. Fact-checked by Ana de Barros, PhD. Simufilam (formerly PTI-125 and sumifilam) is an experimental therapy that Cassava Sciences is developing for Alzheimer’s disease. The investigational small molecule is designed to ease patients’ cognitive symptoms.
Aricept (Donepezil) | Alzheimer's News Today
WEBAricept (donepezil) is an oral medication used to treat the symptoms of dementia caused by Alzheimer’s disease (AD). It is marketed by Eisai in collaboration with Pfizer.. How Aricept works. Aricept is part of a class of drugs called “cholinesterase inhibitors.” It is a reversible inhibitor of an enzyme — a catalyst that can trigger a chemical reaction — called acetylcholinesterase.
Alzheimer's and Brain Awareness Month Brings Fundraisers, …
WEBMay 31, 2022 — Activities Mark Alzheimer’s and Brain Awareness Month Across June. The start of summer holds the promise of beach trips, barbecues, and vacations, but for people with Alzheimer’s disease and their caregivers, family, and friends, June also means Alzheimer’s and Brain Awareness Month. Monthlong initiatives …
Exelon (Rivastigmine) | Alzheimer's News Today
WEBExelon was approved by the U.S. Food and Drug Administration (FDA) in 2000, in capsule form to treat mild to moderate AD based on three main clinical studies.For these three randomized, double-blind studies, a total of 2126 patients were prescribed either Exelon or a placebo for a period of 26 weeks.
Final Protocol for Study of Alzheimer's Therapy Aduhelm …
WEBApr 4, 2022 — Screening of the first patient is expected in May, according to Biogen’s press release.The study will be completed within about four years. The placebo-controlled ENVISION trial was a requirement by the FDA following its accelerated approval of Aduhelm in June 2021 for people with early-stage Alzheimer’s. Delivered as an into-the-vein infusion, clinical data showed that Aduhelm reduced ...
Neurostimulation Device for Alzheimers Granted FDA …
WEBJan 25, 2021 — Non-invasive Neurostimulation Device Wins FDA’s Breakthrough Status. by Patricia Inacio, PhD January 25, 2021. Cognito Therapeutic ’s neurostimulation device — a next-generation digital therapeutic designed to treat memory and cognition symptoms in Alzheimer’s disease — has been granted a breakthrough device designation by the U.S ...
Alzheimer's Patient is First to Get Focused Ultrasound Treatment
WEBNov 30, 2018 — The trial (NCT03671889) is underway and recruiting up to 10 participants — men or women 50-85 years old with probable Alzheimer’s disease.It will be conducted at up to four sites in the United States. This clinical study is examining whether focused ultrasound diminishes the toxic protein aggregates and cognitive dysfunction that are hallmarks of Alzheimer’s disease.
How to Support a Friend With Alzheimer's and Their Family
WEBAug 17, 2020 — The correct response may be to just be there, present in your friend’s mourning and sadness. Respond with a listening ear when your friend needs to vent. You could also find a practical way to get involved to help heal a friend’s heartache. Choose one of the following ideas or come up with a plan that is unique to your friend’s experience ...
What to Do When Elderly Parents Deny They Have Alzheimer's …
WEBJul 19, 2019 — Speak with them about making a plan for the future, one that would position you as protector, trustee, or caregiver. They may deny needing help right now but will be open to making a plan for their future, when they’re old and need it. Fear of the inevitable is a primary reason that a parent denies having Alzheimer’s disease.
Skip to content